Alternative observational designs to estimate the effectiveness of one dose of oral cholera vaccine in Lusaka, Zambia.


Journal

Epidemiology and infection
ISSN: 1469-4409
Titre abrégé: Epidemiol Infect
Pays: England
ID NLM: 8703737

Informations de publication

Date de publication:
13 03 2020
Historique:
pubmed: 14 3 2020
medline: 18 7 2020
entrez: 14 3 2020
Statut: epublish

Résumé

We conducted a matched case-control (MCC), test-negative case-control (TNCC) and case-cohort study in 2016 in Lusaka, Zambia, following a mass vaccination campaign. Confirmed cholera cases served as cases in all three study designs. In the TNCC, control-subjects were cases with negative cholera culture and polymerase chain reaction results. Matched controls by age and sex were selected among neighbours of the confirmed cases in the MCC study. For the case-cohort study, we recruited a cohort of randomly selected individuals living in areas considered at-risk of cholera. We recruited 211 suspected cases (66 confirmed cholera cases and 145 non-cholera diarrhoea cases), 1055 matched controls and a cohort of 921. Adjusted vaccine effectiveness of one dose of oral cholera vaccine (OCV) was 88.9% (95% confidence interval (CI) 42.7-97.8) in the MCC study, 80.2% (95% CI: 16.9-95.3) in the TNCC design and 89.4% (95% CI: 64.6-96.9) in the case-cohort study. Three study designs confirmed the short-term effectiveness of single dose OCV. Major healthcare-seeking behaviour bias did not appear to affect our estimates. Most of the protection among vaccinated individuals could be attributed to the direct effect of the vaccine.

Identifiants

pubmed: 32167038
doi: 10.1017/S095026882000062X
pii: S095026882000062X
pmc: PMC7163804
doi:

Substances chimiques

Cholera Vaccines 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

e78

Références

Lancet. 2005 Jul 2-8;366(9479):44-9
pubmed: 15993232
Epidemiol Rev. 1996;18(2):99-117
pubmed: 9021306
N Engl J Med. 2018 Feb 8;378(6):577-579
pubmed: 29414267
J Clin Epidemiol. 1999 Dec;52(12):1165-72
pubmed: 10580779
Lancet Glob Health. 2016 Nov;4(11):e856-e863
pubmed: 27765293
Lancet Infect Dis. 2012 Nov;12(11):837-44
pubmed: 22954655
JAMA. 1998 Nov 18;280(19):1690-1
pubmed: 9832001
Am J Epidemiol. 1991 Feb 15;133(4):323-31
pubmed: 1899778
N Engl J Med. 2014 May 29;370(22):2111-20
pubmed: 24869721
PLoS One. 2018 Jun 15;13(6):e0199180
pubmed: 29906276
Vaccine. 2016 Jan 20;34(4):479-485
pubmed: 26707378
Vaccine. 2017 Oct 13;35(43):5819-5827
pubmed: 28916247
East Afr Med J. 2013 Oct;90(10):324-31
pubmed: 26862642
Bull World Health Organ. 1985;63(6):1055-68
pubmed: 3879673
Lancet Glob Health. 2015 Mar;3(3):e162-8
pubmed: 25701994
Am J Epidemiol. 1982 Sep;116(3):547-53
pubmed: 7124721
Int J Health Geogr. 2015 Nov 14;14:33
pubmed: 26572873
FEMS Immunol Med Microbiol. 1998 Mar;20(3):201-7
pubmed: 9566491
N Engl J Med. 2016 May 5;374(18):1723-32
pubmed: 27144848
Epidemiol Rev. 1988;10:212-41
pubmed: 3066628
Vaccine. 1990 Jun;8(3):180-9
pubmed: 2194378
Vaccine. 2015 May 15;33(21):2463-9
pubmed: 25850019

Auteurs

A Blake (A)

Epicentre, Paris, France.

O Chewe (O)

Ministry of Health, Lusaka, Zambia.
Zambia National Public Health Institute, Lusaka, Zambia.

J Mwaba (J)

Department of Pathology and Microbiology, University Teaching Hospital, Lusaka, Zambia.
Centre for Infectious Diseases Research in Zambia, Lusaka, Zambia.

G Zulu (G)

Ministry of Health, Lusaka, Zambia.

M Poncin (M)

Médecins Sans Frontières, Geneva, Switzerland.

A Rakesh (A)

Epicentre, Paris, France.

A L Page (AL)

Epicentre, Paris, France.

M L Quilici (ML)

Institut Pasteur, Paris, France.

A S Azman (AS)

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

S Cohuet (S)

Epicentre, Paris, France.

I Ciglenecki (I)

Médecins Sans Frontières, Geneva, Switzerland.

K Malama (K)

Ministry of Health, Lusaka, Zambia.

E Chizema-Kawesha (E)

Ministry of Health, Lusaka, Zambia.

F J Luquero (FJ)

Epicentre, Paris, France.
Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH